Edition:
India

Acarix AB (ACARIX.ST)

ACARIX.ST on Stockholm Stock Exchange

1.10SEK
18 Sep 2020
Change (% chg)

0.20kr (+22.77%)
Prev Close
0.90kr
Open
0.90kr
Day's High
1.10kr
Day's Low
0.90kr
Volume
4,516,993
Avg. Vol
785,932
52-wk High
2.90kr
52-wk Low
0.51kr

Latest Key Developments (Source: Significant Developments)

Acarix Decides On A Guaranteed Rights Issue
Wednesday, 15 Jul 2020 

July 15 (Reuters) - Acarix AB ::REG-ACARIX DECIDES ON A GUARANTEED RIGHTS ISSUE OF APPROXIMATELY SEK 56 MILLION.RESOLVED TO CARRY OUT A NEW SHARE ISSUE OF A MAXIMUM OF 86,156,738 SHARES WITH PREFERENTIAL RIGHTS FOR COMPANY'S EXISTING SHAREHOLDERS.IF FULLY SUBSCRIBED, RIGHTS ISSUE WILL PROVIDE COMPANY WITH APPROXIMATELY SEK 56 MILLION BEFORE DEDUCTION OF COSTS RELATED TO RIGHTS ISSUE.SUBSCRIPTION PRICE: SEK 0.65 PER SHARE.SUBSCRIPTION PERIOD: 21 AUGUST - 4 SEPTEMBER 2020.  Full Article

Acarix Q1 Pretax Loss Narrows To SEK 10.8 Million
Thursday, 14 May 2020 

May 14 (Reuters) - Acarix AB ::Q1 REVENUE AMOUNTED TO 121 KSEK (299), WITH GROSS PROFIT OF 109 KSEK (209) AND A GROSS MARGIN OF 90 PERCENT (70).Q1 PRETAX LOSS SEK 10.8 MILLION VERSUS LOSS SEK 12.8 MILLION YEAR AGO.LARGE PART OF OUR COMMERCIAL ACTIVITIES ARE AFFECTED BY CORRESPONDING SHIFT AS LONG AS COVID-19 CRISIS LASTS.IT IS NOT POSSIBLE TO ESTIMATE FULL POTENTIAL IMPACT FOR ACARIX.  Full Article

Acarix Submits FDA Application
Monday, 16 Dec 2019 

Dec 16 (Reuters) - Acarix AB ::REG-ACARIX SUBMITS FDA APPLICATION.ACARIX AB - FDA REVIEW IS NOW IN PROGRESS AND FDA'S AMBITION IS TO SHARE ITS INITIAL FEEDBACK WITHIN 150 DAYS.ACARIX - PROCESS DURATION IS HARD TO PREDICT AS IT DEPENDENS ON FDA'S COMMENTS, REQUESTS FOR ADDITIONAL INFORMATION.  Full Article

Acarix CADScorSystem Included In NICE Guidelines In UK
Thursday, 27 Jun 2019 

June 27 (Reuters) - Acarix Ab ::ACARIX CADSCOR®SYSTEM INCLUDED IN NICE GUIDELINES (UK).CADSCOR SYSTEM INCLUDED AS FIRST LINE INVESTIGATION FOR RULING OUT SUSPECTED STABLE CORONARY ARTERY DISEASE BY BRITISH NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE).INCLUSION IN NICE GUIDELINES WILL ALLOW ACARIX TO ACCELERATE ITS STRATEGY OF INTRODUCING CADSCOR IN UK.  Full Article

Acarix Gets Order From German Clinic
Monday, 10 Dec 2018 

Dec 10 (Reuters) - Acarix AB ::REG-GERMAN CLINIC ORDERS SECOND ACARIX CADSCOR®SYSTEM TO FURTHER BOOST PATIENT CAPACITY.  Full Article

Acarix Q3 Pretax Loss Widens To SEK 12.7 Million
Wednesday, 14 Nov 2018 

Nov 14 (Reuters) - Acarix AB ::REG-CUSTOMER EVALUATION OF CADSCOR®SYSTEM COMPARES FAVORABLY AGAINST EXISTING METHODS.Q3 PRETAX LOSS SEK 12.7 MILLION VERSUS LOSS SEK 7.5 MILLION YEAR AGO.  Full Article

Acarix announced that the board of directors has appointed Per Persson to Chief Executive Officer
Wednesday, 14 Nov 2018 

Nov 13 (Reuters) - Acarix AB ::REG-ACARIX (FN STO: ACARIX) TODAY ANNOUNCED THAT THE BOARD OF DIRECTORS HAS APPOINTED PER PERSSON TO CHIEF EXECUTIVE OFFICER.BOARD OF DIRECTORS HAS APPOINTED PER PERSSON TO CHIEF EXECUTIVE OFFICER.CHRISTIAN LINDHOLM, WHO HAS SERVED AS INTERIM CEO SINCE FEBRUARY 2018, RESUMES HIS ROLE AS CHIEF FINANCIAL OFFICER.THE CHANGES ARE EFFECTIVE IMMEDIATELY.  Full Article

Acarix Signs Agreement With MED Management For German Outpatient Market
Wednesday, 10 Oct 2018 

Oct 10 (Reuters) - Acarix AB ::REG-ACARIX AB ENTERS STRATEGIC ALLIANCE WITH MED MANAGEMENT TO BROADEN THE COMMERCIAL PLATFORM TOWARD THE GERMAN OUTPATIENT MARKET.  Full Article

BRIEF-Acarix Q1 Pretax Loss Narrows To SEK 10.8 Million

* Q1 REVENUE AMOUNTED TO 121 KSEK (299), WITH GROSS PROFIT OF 109 KSEK (209) AND A GROSS MARGIN OF 90 PERCENT (70)